At SCOPE 2026, SubjectWell CEO Fred Martin shared a clear message: clinical trials have an experience problem.
Across the industry, recruitment and retention remain the single biggest barrier to trial success. Despite advances in technology, global expansion, and growing investment, sponsors and CROs continue to face the same fundamental challenges: delays, rising costs, and unpredictable enrollment timelines.
The reason is simple. Most clinical trials are still designed around regulatory processes rather than people.
The future belongs to organizations that rethink patient engagement from the ground up.
The clinical trial conundrum
Modern trials are more complex than ever. They span countries, regulatory environments, and healthcare systems. They rely on multiple vendors, disconnected tools, and fragmented data flows.
This creates real consequences:
- Localization and compliance challenges across regions
- Inconsistent patient experiences across vendors and channels
- Data variability and operational inefficiencies
- Increased cost and slower timelines
- Underpowered studies and missed milestones
But perhaps the most important issue is cultural. Patients are still too often treated as inputs to a process rather than participants in a journey. When engagement feels transactional instead of relational, trust erodes, and recruitment and retention suffer.
Why the industry is shifting toward patient-first trial design
This shift is being reinforced by forces across the clinical research ecosystem, especially in the U.S. and Europe.
Regulators, sponsors, and CROs are increasingly elevating patient-first approaches, including more formalized expectations around patient engagement and patient experience data. At the same time, patients now expect consumer-grade digital experiences like eConsent and remote-friendly support, and they are less willing to tolerate friction, confusion, or opaque communication.
Diversity, equity, and access have also become clinical imperatives. Trials must be designed to reduce barriers and reflect real-world populations, not just ideal recruitment conditions.
And as studies grow more complex, patient experience is no longer secondary to speed and predictability. It directly shapes enrollment velocity, retention, protocol adherence, and the quality and consistency of trial data.
What sponsors and CROs actually need
The industry needs alignment. Fred emphasized three capabilities that define the next generation of clinical trial execution:
A unified view of the patient journey
Sponsors must be able to understand and manage the full experience across every touchpoint, from awareness to enrollment to retention.
Global reach with local trust
Successful global trials require more than translation. They require cultural understanding, localized engagement, and community credibility.
Data-driven decision-making
Patient engagement must be measurable, adaptive, and continuously optimized, rather than static or reactive.
Why fragmented solutions no longer work
Traditional operating models rely on multiple vendors performing narrow functions, such as recruitment, engagement, retention, data management, and support services. This results in vendor sprawl.
This fragmentation creates gaps in accountability, inconsistent patient experiences, and inefficiencies that slow trials down. It also makes it difficult to measure outcomes holistically or scale globally. To move forward, the industry must shift from managing vendors to managing experiences.
That requires integrated platforms that deliver measurable impact on speed, quality, and cost.
The rise of the global patient experience platform
Clinical research needs a unified ecosystem designed around the patient journey from end to end.
A true patient experience platform should contain several essential capabilities:
- Comprehensive creative strategy and services that build trust and drive awareness
- Global reach that expands access and improves diversity
- Science-centered frameworks that account for patient and site burden and real-world standards of care
- Human-centered services that support engagement, reduce barriers, and strengthen retention
- Interoperable technology that enables precision, real-time insight, and operational efficiency
Together, these elements transform recruitment from a tactical activity into a coordinated experience strategy.
Better experiences create better outcomes
When trials are designed around patient experience, everyone benefits.
Patients experience:
- Clear, transparent communication
- Reduced friction and confusion
- Respect for time, privacy, and individual needs
- Meaningful engagement that builds trust rather than fatigue
Sponsors and CROs gain:
- Faster enrollment timelines
- Stronger retention and protocol adherence
- Higher-quality data
- Greater predictability and scalability in global trials
In other words, improving patient experience is not a soft metric. It is a core driver of operational performance.
The future is co-designed with patients
Clinical trials are entering a new era that is defined by global scale, increasing complexity, and rising expectations from regulators and participants alike.
Success will not come from optimizing individual tactics, but from rethinking how trials are designed, delivered, and experienced.
The organizations that lead the future of clinical research will be those that co-design trials with patients at every step, not just during recruitment.
Because when patient experience improves, everything else follows.
